Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Decibel Therapeutics, Inc. - Common Stock (NQ:DBTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Decibel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq -
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sovos Brands, Inc. (Nasdaq - SOVO), Zynerba Pharmaceuticals, Inc. (Nasdaq - ZYNE), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ElectraMeccanica (Nasdaq - SOLO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - DBTX)
From Brodsky & Smith LLC
Via GlobeNewswire
DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX
From Kahn Swick & Foti, LLC
Via Business Wire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be... 
Via Benzinga
Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
 
Via Benzinga
Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on... 
Via Benzinga
Dow Edges Higher; Tigo Energy Shares Plunge
U.S. stocks pared some losses toward the end of trading, with the Dow Jones turning higher on Wednesday. The Dow traded up 0.05% to 35,332.35 while the NASDAQ fell 0.46% to 13,820.37. The S&P 500, also... 
Via Benzinga
Topics Stocks
Why Cutera Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Wednesday's Session
Gainers Tango Therapeutics, Inc. (NASDAQ: TNGX) climbed 85.2% to $7.09 after gaining 11% on Tuesday. Tango Therapeutics recently posted a narrower quarterly loss. 
Via Benzinga
Akamai Technologies, Array Technologies Music, HNI, PENN Entertainment And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Nasdaq Down 1%; Decibel Therapeutics Shares Spike Higher
U.S. stocks were lower midway through trading, with the Nasdaq Composite falling around 1% on Wednesday. The Dow traded down 0.52% to 35,130.45 while the NASDAQ fell 1.03% to 13,741.71. The S&P 500,... 
Via Benzinga
Topics Stocks
Health Care Company Regeneron Pharmaceuticals Announces Acquisition of Decibel Therapeutics
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
 
Via Benzinga
Why Is Tango Therapeutics (TNGX) Stock Up 117% Today?
Tango Therapeutics (TNGX) stock is soaring higher on Wednesday after getting a couple of updates from analysts covering the shares. 
Via InvestorPlace
YELL Stock Alert: Yellow Receives Nasdaq Delisting Notice
Yellow (YELL) stock is falling on Wednesday after the struggling U.S. trucking company received a Nasdaq delisting notice! 
Via InvestorPlace
DBTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Decibel Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
US Stocks Edge Lower; Charles River Earnings Top Estimates
U.S. stocks were mostly lower this morning, with the Nasdaq Composite falling more than 50 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.03% to 35,303.64 while the... 
Via Benzinga
Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal
Decibel Therapeutics (DBTX) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (REGN). 
Via InvestorPlace
Decibel Therapeutics Stock Soars on Acquisition Deal - The Details
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has agreed to acquire Decibel Therapeutics Inc (NASDAQ: DBTX) at $4.00 per share with an additional contingent value right of up to $3.50 per share in cash... 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - DBTX)
From Brodsky & Smith LLC
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs
From Regeneron Pharmaceuticals, Inc.; Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemotherapy 
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy Summit
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
From Decibel Therapeutics, Inc.
Via GlobeNewswire
Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO
CTA authorization provides approval for the Company to expand its planned CHORD™ Phase 1/2 clinical trial of DB-OTO to patients in Spain aged two years and younger 
From Decibel Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.